Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma

Similar Items

• Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study
  od: Liang, Sheng-Kai, i dr.
  Izdano: (2018)
• Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
  od: Liang, Sheng-Kai, i dr.
  Izdano: (2021)
• Real-world progression-free survival of first line afatinib patients with EGFR-mutant advanced lung adenocarcinoma: A multicentre study in Indonesia
  od: Noni Novisari Soeroso, i dr.
  Izdano: (2025-01-01)
• Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
  od: Lu, Shun, i dr.
  Izdano: (2021)
• Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
  od: Gwo-Fuang Ho, i dr.
  Izdano: (2019-09-01)